A study that sequentially delivered doxorubicin and Bcl-2-targeting siRNAs by respectively encapsulating each agent in tumor-homing nanoparticles found that the sequential treatments significantly achieved optimal efficacy in PC3-tumor-bearing mice [29]. This evidence concerns the gene BCL2 and neoplasm.